Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
EMBO J ; 43(11): 2198-2232, 2024 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-38649536

RESUMO

Nuclear pore complex (NPC) biogenesis is a still enigmatic example of protein self-assembly. We now introduce several cross-reacting anti-Nup nanobodies for imaging intact nuclear pore complexes from frog to human. We also report a simplified assay that directly tracks postmitotic NPC assembly with added fluorophore-labeled anti-Nup nanobodies. During interphase, NPCs are inserted into a pre-existing nuclear envelope. Monitoring this process is challenging because newly assembled NPCs are indistinguishable from pre-existing ones. We overcame this problem by inserting Xenopus-derived NPCs into human nuclear envelopes and using frog-specific anti-Nup nanobodies for detection. We further asked whether anti-Nup nanobodies could serve as NPC assembly inhibitors. Using a selection strategy against conserved epitopes, we obtained anti-Nup93, Nup98, and Nup155 nanobodies that block Nup-Nup interfaces and arrest NPC assembly. We solved structures of nanobody-target complexes and identified roles for the Nup93 α-solenoid domain in recruiting Nup358 and the Nup214·88·62 complex, as well as for Nup155 and the Nup98 autoproteolytic domain in NPC scaffold assembly. The latter suggests a checkpoint linking pore formation to the assembly of the Nup98-dominated permeability barrier.


Assuntos
Complexo de Proteínas Formadoras de Poros Nucleares , Poro Nuclear , Anticorpos de Domínio Único , Complexo de Proteínas Formadoras de Poros Nucleares/metabolismo , Poro Nuclear/metabolismo , Humanos , Anticorpos de Domínio Único/metabolismo , Animais , Xenopus , Xenopus laevis , Células HeLa
2.
Nat Commun ; 15(1): 3827, 2024 May 07.
Artigo em Inglês | MEDLINE | ID: mdl-38714735

RESUMO

The main protease (Mpro) of SARS-CoV-2 is critical for viral function and a key drug target. Mpro is only active when reduced; turnover ceases upon oxidation but is restored by re-reduction. This suggests the system has evolved to survive periods in an oxidative environment, but the mechanism of this protection has not been confirmed. Here, we report a crystal structure of oxidized Mpro showing a disulfide bond between the active site cysteine, C145, and a distal cysteine, C117. Previous work proposed this disulfide provides the mechanism of protection from irreversible oxidation. Mpro forms an obligate homodimer, and the C117-C145 structure shows disruption of interactions bridging the dimer interface, implying a correlation between oxidation and dimerization. We confirm dimer stability is weakened in solution upon oxidation. Finally, we observe the protein's crystallization behavior is linked to its redox state. Oxidized Mpro spontaneously forms a distinct, more loosely packed lattice. Seeding with crystals of this lattice yields a structure with an oxidation pattern incorporating one cysteine-lysine-cysteine (SONOS) and two lysine-cysteine (NOS) bridges. These structures further our understanding of the oxidative regulation of Mpro and the crystallization conditions necessary to study this structurally.


Assuntos
Domínio Catalítico , Proteases 3C de Coronavírus , Cisteína , Dissulfetos , Oxirredução , SARS-CoV-2 , Dissulfetos/química , Dissulfetos/metabolismo , SARS-CoV-2/metabolismo , SARS-CoV-2/química , Proteases 3C de Coronavírus/metabolismo , Proteases 3C de Coronavírus/química , Cisteína/química , Cisteína/metabolismo , Cristalografia por Raios X , Humanos , Modelos Moleculares , Multimerização Proteica , COVID-19/virologia
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa